HC Wainwright Issues Positive Forecast for CG Oncology (NASDAQ:CGON) Stock Price

CG Oncology (NASDAQ:CGON) had its price target lifted by HC Wainwright from $80.00 to $100.00 in a report published on Tuesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other equities research analysts have also recently issued reports on CGON. Wall Street Zen cut shares of CG Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Royal Bank Of Canada lifted their price objective on shares of CG Oncology from $61.00 to $73.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 21st. Truist Financial lifted their price objective on shares of CG Oncology from $66.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday, February 10th. Morgan Stanley set a $93.00 price objective on shares of CG Oncology in a research report on Friday, January 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CG Oncology in a research report on Wednesday, January 21st. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, CG Oncology presently has an average rating of “Moderate Buy” and an average price target of $70.67.

CG Oncology Stock Up 3.3%

Shares of CGON stock opened at $69.81 on Tuesday. CG Oncology has a 52 week low of $14.80 and a 52 week high of $69.90. The stock has a market capitalization of $5.89 billion, a PE ratio of -33.72 and a beta of 0.70. The firm has a 50 day moving average of $59.73 and a two-hundred day moving average of $48.88.

CG Oncology (NASDAQ:CGON) last issued its quarterly earnings results on Friday, February 27th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.10. The business had revenue of $2.32 million during the quarter. Analysts expect that CG Oncology will post -1.31 EPS for the current fiscal year.

Insider Buying and Selling

In other CG Oncology news, Director James Mulay sold 11,145 shares of CG Oncology stock in a transaction on Friday, January 9th. The shares were sold at an average price of $52.47, for a total value of $584,778.15. The transaction was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 7.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Whittier Trust Co. of Nevada Inc. acquired a new position in CG Oncology in the fourth quarter valued at $27,000. Strengthening Families & Communities LLC acquired a new position in CG Oncology in the third quarter valued at $40,000. Comerica Bank increased its stake in CG Oncology by 100.4% in the fourth quarter. Comerica Bank now owns 1,028 shares of the company’s stock valued at $43,000 after purchasing an additional 515 shares during the period. Picton Mahoney Asset Management acquired a new position in CG Oncology in the fourth quarter valued at $118,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in CG Oncology by 33.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company’s stock valued at $163,000 after purchasing an additional 972 shares during the period. 26.56% of the stock is currently owned by institutional investors and hedge funds.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.